Ardena Acquires Catalent's Somerset, New Jersey Drug Product Facility

GHO Capital Acquires Ardena, a European Early‑Stage CDMO

January 9, 2020

Pharmaceuticals

GHO Capital Partners LLP has acquired Ardena, a Belgium‑headquartered contract development and manufacturing organisation (CDMO) focused on early‑phase drug development, from Mentha Capital and existing management. GHO will partner with Ardena's management to accelerate international growth, broaden the company’s service offering and build a fully integrated early‑stage CDMO platform through organic and inorganic expansion.

Ardena (GHO Capital Portfolio) Acquires Idifarma from Suanfarma and Sodena

September 2, 2021

Healthcare Services

Ardena, a GHO Capital-backed specialist pharmaceutical CDMO, has acquired Idifarma from Suanfarma and Sodena. The deal expands Ardena's European footprint and adds Idifarma's spray drying technology and high-potency drug capabilities at its Pamplona site, supporting Ardena's integrated end-to-end CDMO strategy.

Novo Holdings Acquires Catalent for $16.5 Billion

December 18, 2024

Healthcare Services

Novo Holdings has completed its previously announced all-cash acquisition of Catalent, Inc. for an enterprise value of approximately $16.5 billion, with Catalent stockholders receiving $63.50 per share. Shortly after closing, Novo Nordisk will acquire three Catalent fill-finish sites (Anagni, Italy; Bloomington, Indiana; and Brussels, Belgium) and related assets from Novo Holdings.

Catalent Acquires Bettera Brands from Highlander Partners for $1 Billion

August 30, 2021

Food & Beverage

Catalent, Inc. agreed to acquire Bettera Holdings, LLC (Bettera Brands) from Highlander Partners for $1 billion. The acquisition expands Catalent's consumer health and nutraceutical manufacturing capabilities—adding Bettera's gummy, soft chew, and lozenge production capacity and approximately 500 employees across four U.S. facilities.

LGM Pharma Acquires Nexgen Pharma's Drug Product CDMO Business

July 23, 2020

Pharmaceuticals

LGM Pharma has acquired the formulation development and drug product contract manufacturing business of Nexgen Pharma, expanding LGM's CDMO capabilities and U.S.-based manufacturing footprint. Financial support for the transaction was provided by private equity firm New Harbor Capital; Nexgen Pharma sold its pharmaceutical CDMO unit to allow the company to focus on other healthcare segments.

Adare Pharma Solutions Acquires Frontida BioPharm

December 1, 2021

Pharmaceuticals

Adare Pharma Solutions, a PE-backed contract development and manufacturing organization (CDMO), has acquired Frontida BioPharm, a vertically integrated CDMO focused on oral formulations. The deal expands Adare’s capabilities—including high-potency compound handling and packaging services—and increases its manufacturing footprint; Adare is backed by Thomas H. Lee Partners and Frazier Healthcare Partners.